- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: Immunoscore.
Displaying page 1 of 1.
EudraCT Number: 2020-000401-91 | Sponsor Protocol Number: iMAGINE | Start Date*: 2020-06-26 | |||||||||||
Sponsor Name:Medizinische Universität Wien | |||||||||||||
Full Title: iMmunoscore Associated decision GuIdance for adjuvaNt chemotherapy and physical Exercise in stage III colon cancer (iMAGINE): a prospective, randomized, open-label, multicenter, phase III clinical ... | |||||||||||||
Medical condition: • Histologically confirmed stage III carcinoma of the colon • Medical need for an standard adjuvant chemotherapy • Suitable to withstand the course of an standard adjuvant chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001277-17 | Sponsor Protocol Number: 2017/2536 | Start Date*: 2017-12-22 | |||||||||||
Sponsor Name:Gustave Roussy | |||||||||||||
Full Title: Adjuvant immunotherapy after salvage surgery in head and neck squamous cell carcinoma : phase 2 trial evaluating the efficacy and the toxicity of nivolumab alone, and of the combination nivolumab ... | |||||||||||||
Medical condition: high risk recurrent head and neck squamous cell carcinoma (HNSCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001328-17 | Sponsor Protocol Number: IMIB-HTF-2021-01 | Start Date*: 2021-09-23 |
Sponsor Name:Fundación para la formación e investigación sanitarias de la Región de Murcia | ||
Full Title: Histological and clinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1. | ||
Medical condition: Colorectal cancer and triple negative breast cancer patients (TNBC) who shown overexpression of fascin1 in the diagnostic biopsy tissue. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004927-27 | Sponsor Protocol Number: RELAIS | Start Date*: 2014-12-17 |
Sponsor Name:Med. Univ. Wien, Innere Med. I | ||
Full Title: REgorafenib’s Liquid BiopsY (RELY): A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer. a non-profit investigator-init... | ||
Medical condition: non-resectable pretreated colorectal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003739-12 | Sponsor Protocol Number: NICOLE | Start Date*: 2018-01-29 | |||||||||||||||||||||
Sponsor Name:SOCIETà CAMPANA DI IMMUNOTERAPIA ONCOLOGICA | |||||||||||||||||||||||
Full Title: Preoperative Nivolumab in patients with locally advanced colon cancer (T3 or T4): a window-of-opportunity study | |||||||||||||||||||||||
Medical condition: colon cancer: a window-of-opportunity study | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000131-51 | Sponsor Protocol Number: 1921 | Start Date*: 2019-03-07 | ||||||||||||||||
Sponsor Name:Zealand University Hospital | ||||||||||||||||||
Full Title: Preoperative endoscopic treatment with fosfomycin and metronidazole in patients with right-sided colon cancer and colon adenoma: a clinical proof-of-concept intervention study MEFO trial | ||||||||||||||||||
Medical condition: Colon cancer in track 1. Colon adenoma in track 2. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-004841-17 | Sponsor Protocol Number: NEO-TIM | Start Date*: 2020-08-18 | |||||||||||
Sponsor Name:FONDAZIONE MELANOMA ONLUS | |||||||||||||
Full Title: A phase II randomized non-comparative study, with neoadjuvant plus adjuvant therapy with combination or sequence of vemurafenib, cobImetinib, and atezolizuMab in patients with high-risk, surgically... | |||||||||||||
Medical condition: high-risk, surgically resectable BRAF mutated and wild-type melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000914-12 | Sponsor Protocol Number: GASOLINE | Start Date*: 2020-06-12 | ||||||||||||||||||||||||||
Sponsor Name:University of Cologne | ||||||||||||||||||||||||||||
Full Title: Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors | ||||||||||||||||||||||||||||
Medical condition: • Melanoma: unresectable stage III with macroscopic lymph node, in transit/satellite metastasis or stage IV after ≥ 2 lines of therapy (incl. checkpoint blockade, BRAF inhibitor) • Prostate carcino... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
